VivoSeq
Oncology

Prostate Carcinoma

54

Pipeline Programs↗

19

Active Trials↗

27

Companies Involved↗

Prostate Carcinoma is a moderately active landscape with 54 programs across 27 companies. The most active players are Amgen, Moderna, Prostate Oncology Specialists, Inc.. 20 therapies are approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

62/100

Pipeline Velocity

32/100

Mech. Concentration

15/100

Completion Rate

79/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

1 program

Phase 1Moderna logo

Moderna

1 program

Phase 1P

Prostate Oncology Specialists, Inc.

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2EMD Serono logo

EMD Serono

1 program

Phase 2Teva logo

Teva

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical5

Prilocaine

Dentsply International

Bupivacaine

Innocoll

Firmagon

Ferring

Androgen Deprivation Therapy

Johnson & Johnson

Eligard Exposure

Astellas

Phase 16

Mrna-4394

Moderna

Ipilimumab

Bristol-Myers Squibb

Drug: 68-Ga PSMA11

University of Texas Southwestern Medical Center

68ga-PSMA-11

University of Texas Southwestern Medical Center

AMG 333

Amgen

Phase 214

Carboplatin

Avyxa

Sipuleucel-T

Prostate Oncology Specialists, Inc.

Pembrolizumab

Merck & Co.

Thalidomide

Bristol-Myers Squibb

Durvalumab

AstraZeneca

Phase 39

Goserelin Acetate

AstraZeneca

Docetaxel

Avyxa

Novartis-Pluvicto

Novartis

Prednisone

Roxane Laboratories

Leuprolide Acetate

Eastern Cooperative Oncology Group

Approved20

Darolutamide

Bayer

Hydroxychloroquine

Alnylam Pharmaceuticals

Zoledronic Acid

Pfizer

Flutamide

Schering-Plough

Finasteride

Organon and Co

Analysis

Modality Breakdown

90%

Small molecule

43 of 48 classified programs — the dominant modality here.

10%ALL OTHERSMonoclonal antibody36%RNA therapy12%Cell therapy12%

Small molecule leads; the ring shows all 48 classified programs, each share of the total. Modality classified for 89% of 57 pipeline programs.

Analysis

Trial Status

35

clinical trials

Recruiting12 · 34%
Completed11 · 31%
Active, not recruiting5 · 14%
Unknown status2 · 6%
Terminated2 · 6%
Withdrawn1 · 3%
Other2 · 6%

Clinical Trials

Trial Activity

35 trials

The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma
Recruiting·UUniversity Hospital Tuebingen·Phase 1·NCT04104607·86 enrolled
A Multicentric, Observational, Post-marketing, Registry Study to Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.
Recruiting·XXEOS Medical·N/A·NCT06970275·850 enrolled
Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)
Recruiting·NNYU Langone Health·Preclinical·NCT07142967·28 enrolled
Outcomes After PSMA PET-Guided Progression-Directed Radiotherapy, Including SBRT and Brachytherapy, for Oligoprogressive Prostate Cancer: An Ambispective Multicenter Real-World Evidence Cohort Study
Recruiting·AAffidea Nu-med Center of Oncological DIagnostics and Therapy·N/A·NCT07691697·1,000 enrolled
Improving Cryoablation Efficacy With BARRigel Rectal Spacing (ICE-BARR) Trial
Recruiting·NNYU Langone Health·Preclinical·NCT07567027·20 enrolled
Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer: a Randomized Phase II Trial
Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT06927635·75 enrolled
Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification
Recruiting·JJonsson Comprehensive Cancer Center·N/A·NCT04765150·275 enrolled
Treatment Patterns and Characteristics of Patients Receiving Androgen Receptor Pathway Inhibitors in a Real-world Setting in -Australia: A Retrospective Prescriptions Data Study (TARA)
Recruiting·Bayer logoBayer·N/A·NCT07223372·1,000 enrolled
Total en Bloc Urethra Preservation at Robot-assisted Prostatectomy (ToP-RAP): A Prospective IDEAL Stage 2a Study
Recruiting·—·Preclinical·NCT07678489·60 enrolled
High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)
Recruiting·CCedars-Sinai Medical Center·Phase 2·NCT07223385·80 enrolled
Phase II Trial of Primary Radiotherapy With Androgen Ablation With or Without Adjuvant Niraparib for Selected High-Risk Locoregional Prostate Cancer
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04947254·200 enrolled
MRI-Guided HDR Brachytherapy for Prostate Cancer
Recruiting·UUniversity Health Network, Toronto·Preclinical·NCT00913939·500 enrolled
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide With Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) Following PSA Response in Participants With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT05884398·420 enrolled
The Effect of Intraprostatic Local Anesthesia on Pain Perception During Transperineal Prostate Biopsy Under Local Anesthesia
Active, not recruiting·MMarmara University·Preclinical·NCT07683182·50 enrolled
Investigation Into Detection of Prostate Cancer Using Voided Urine
Active, not recruiting·TThomas Jefferson University·N/A·NCT04788277·810 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)